What is the market's earnings forecast for Cronos Group next quarter?

What guidance did Cronos Group's management provide for the next earnings period?

What is the revenue and EPS growth rate for Cronos Group year over year?

What does Cronos Group do and what are its main business segments?

What were the key takeaways from Cronos Group's earnings call?

What factors drove the changes in Cronos Group's revenue and profit?

What were the key takeaways from Cronos Group’s earnings call?

What is Cronos Group's latest dividend and current dividend yield?

- **Revenue Surge**: 25% organic growth in 2025, Q4 net revenue up 47% YoY to $44.5 million, driven by Canada and Israel.
- **Market Leadership**: Spinach vapes #1 in cartridges, Sourz edibles #1 in multi-packs, Lord Jones #1 in hash pre-rolls.
- **Innovation Success**: PUFFERZ vapes launched in Q4, Sourz edibles maintain 22% market share.
- **Strategic Expansion**: $67.5M acquisition of CanAdelaar to enter Netherlands' adult-use market, 72 retailers with exclusive supply.
- **Financial Resilience**: $832M cash, no debt, 43% full-year gross margin, and $16.2M Adjusted EBITDA.

**【CEO Summary Section】**
- **Record Revenue Growth**: Cronos achieved 25% organic net revenue growth in 2025, driven by strong performance in Canada, Israel, and international markets. Q4 net revenue reached $44.5 million, up 47% YoY.
- **Canada Market Dominance**: Spinach brand led with 42% YoY revenue growth, including top-performing vapes (Cherry Crush, Blueberry Dynamite) and edibles (Fully Blasted multi-packs). Lord Jones maintained leadership in hash and live resin pre-rolls.
- **Israel Expansion**: PEACE NATURALS posted 52% YoY revenue growth, remaining the top-selling brand. International markets (excluding Israel) grew 68% YoY, driven by Germany normalization and demand.
- **Innovation Highlights**: Launch of PUFFERZ all-in-one vape devices in Canada, with plans for broader distribution in 2026. Sourz edibles maintained 22% market share.
- **Strategic Acquisitions**: $67.5 million USD acquisition of CanAdelaar, the Netherlands' largest adult-use cannabis producer, to expand European presence and leverage borderless product strategy.
- **Financial Strength**: $832 million in cash equivalents, no debt, and active share repurchase program reducing share count in 2025.

**【CFO Financial Commentary】**
- **Q4 Financials**: GAAP net revenue $44.5 million (+47% YoY), Adjusted EBITDA $0.5 million (vs. -$7.2 million YoY). Full-year Adjusted EBITDA $16.2 million, up 14% YoY.
- **Gross Margin**: Q4 Adjusted gross margin 36% (vs. 30% YoY), driven by higher-margin Israel and international sales. Full-year margin 43%, reflecting stabilization post-Groco expansion.
- **Cost Management**: Operating expenses $22.5 million (flat YoY), with disciplined spending on R&D and innovation.
- **Cash Flow**: $832 million cash balance, supporting M&A and growth initiatives. Q4 cash flow from operations $18 million, offset by $7 million working capital outflow.

**【Q&A Highlights】**
- **Product Allocation**: Post-Groco expansion, Canada and Europe will see increased product allocation, with focus on margin and demand. Q4 supply constraints eased in 2026.
- **Gross Margin Outlook**: 2025 full-year 43% margin seen as sustainable, with potential expansion from CanAdelaar (not included in current guidance).
- **CanAdelaar Impact**: Transaction expected to close in H1 2026, with accretive EBITDA from Netherlands' 72 adult-use retailers.
- **CapEx**: 2026 spend expected under $10 million, supporting operational efficiency.
- **Downstream Assets**: Preference for marketing partnerships over ownership in Germany and U.S., given regulatory uncertainty.
- **U.S. Strategy**: Lessons from PharmaCann option: prioritize regulatory clarity and control over market entry.

Cronos Group Inc (CRON) Q4 2025 Earnings Call Transcript

- **Record Growth**: Q3 2025 net revenue up 6% YoY to $36.3 million, driven by Israel and Canadian extract sales.\n- **Israel Leadership**: Peace Naturals holds 4.5% overall market share, with Wedding Cake as #1-selling strain.\n- **GroCo Expansion Impact**: 70% flower capacity increase expected in 2026, offsetting Q3 2025 supply constraints.\n- **Profitability**: 50% gross margin (vs. 31% YoY) and $5.7 million adjusted EBITDA reflect operational efficiency.\n- **Global Momentum**: Peace Naturals in 7 markets, with Germany and Switzerland leading international expansion.

**【CEO Summary Section】**
- **Record Q3 2025 Performance**: Net revenue of $36.3 million, up 6% YoY, driven by Israel and Canadian extract sales.\n- **Israel Dominance**: Peace Naturals leads medical cannabis market with 4.5% overall share, and flagship strains like Wedding Cake rank #1.\n- **Canada Recovery**: Edibles (19.7% share) and vapes (9.5% share) offset flower supply constraints; GroCo expansion begins in Q3 but full impact expected in 2026.\n- **Global Expansion**: Peace Naturals available in 7 markets, with Germany and Switzerland leading international growth.\n- **Strong Balance Sheet**: $824 million in cash, no debt, supporting growth investments.\n
**【CFO Financial Commentary】**
- **Gross Margin Improvement**: 50% (vs. 31% YoY), driven by Israel mix shift, higher prices, and production efficiencies.\n- **Cost Control**: Operating expenses down 18% YoY to $18.6 million; adjusted EBITDA up to $5.7 million.\n- **Cash Flow**: $19.1 million positive from operations, offset by $18.4 million High Tide investment and $1.9 million share buybacks.\n
**【Q&A Key Highlights】**
- **GroCo Expansion Timing**: Q3 2025 sales minimal; 2026 capacity increase to 70% expected to drive flower revenue growth.\n- **Gross Margin Outlook**: Blended Q2/Q3 margins (50%) indicative of current trends; future improvements from fixed cost absorption.\n- **Supply Constraints**: Canada flower shortages impacted Q3, but 2026 GroCo ramp-up expected to resolve.\n- **International Shipment Timing**: Q4 revenue delayed from Q3, but H2 2025 international net revenue similar to H1.

Cronos Group Inc (CRON) Q3 2025 Earnings Call Transcript

- **Revenue growth accelerates**: $33.5M (+21% YoY) driven by international expansion and Israel market dominance.
- **Market leadership**: Spinach #2 in Canada (4.7% flower share), Lord Jones #1 in premium pre-rolls (28.5%).
- **Gross margin soars**: 43% vs. 23% YoY, fueled by high-margin international sales and GrowCo consolidation.
- **Strategic investment**: $18.5M in High Tide with potential 8%+ yield, enhancing cannabis ecosystem ties.
- **Global expansion**: PEACE NATURALS now in 7 markets, Israel revenue +36% YoY.

**【CEO Opening Remarks】**
- Q2 2025 net revenue: $33.5 million (+21% YoY), driven by flower sales in international markets and Israel, plus GrowCo consolidation.
- Spinach brand: #2 in Canada with 4.7% market share (flower), #4 in vapes (6.5%), and 20% share in edibles.
- Lord Jones: #1 in hash-infused pre-rolls (28.5%), launching new Live Resin Caviar products.
- International growth: Israel revenue +36% YoY, Germany largest contributor to global growth.
- Israel duty update: Proposed import duty rejected, maintaining leadership in medical cannabis.
- Global expansion: PEACE NATURALS now in 7 markets (Canada, Israel, Germany, UK, Australia, Switzerland, Malta).
- Balance sheet: $834M cash, no debt.

**【CFO Financial Commentary】**
- Gross profit: $14.5M (43% margin vs. 23% YoY), driven by GrowCo consolidation and higher-margin markets.
- Operating expenses: $19.1M (-11% YoY), G&A down $2.2M.
- Adjusted EBITDA: $1.7M (vs. -$11M YoY), improving due to revenue mix and cost control.
- Cash flow: $834M ending balance, $7M working capital outflow, $18.5M invested in High Tide via convertible loan.
- High Tide investment: 5-year loan with 4% interest, convertible at CAD 4.20/share, plus warrants at CAD 3.91.

**【CEO Closing Remarks】**
- Key priorities: Expand GrowCo capacity (flower sales start Q4), strengthen Canada share with new supply, grow international markets, maintain cost discipline.
- Fall 2025 outlook: New GrowCo capacity to relieve flower supply constraints and drive growth.


Cronos Group Inc. (CRON) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: 28% YoY to $32.3M, driven by Israel (+40% YoY) and premium product demand.
- **Margin Expansion**: Adjusted gross margin jumps to 44% (vs. 18% last year), EBITDA turns positive at $2.3M.
- **Capacity Catalyst**: GrowCo expansion to resolve flower shortages by H2 2025, positioning for long-term margin improvement.
- **Israel Risk**: Tariff threat remains, but Cronos maintains 30% market share as largest medical provider.
- **Balance Sheet Strength**: $838M cash, no debt, $50M buyback announced.


**【CEO Key Updates】**
- **Brand Performance**: Spinach brand holds 4.6% market share in Canada, ranking 2nd overall and 3rd in flower category. Lord Jones leads hash-infused pre-rolls with 30.1% share. Sourz edibles dominate gummies (23% share) with new cannabinoid-infused products.
- **Israel Growth**: Cronos Israel revenue up 40% YoY, contributing 30% of total net revenue. Despite proposed tariffs, Israel remains key market with strong patient trust.
- **Capacity Expansion**: GrowCo expansion to address supply constraints, expected to unlock capacity in H2 2025. Current flower shortages driven by demand for premium products.
- **Financial Strength**: $838M cash balance, no debt. Announced $50M share buyback program.

**【CFO Financial Highlights】**
- **Q1 2025 Results**: Consolidated net revenue $32.3M (+28% YoY), adjusted gross margin 44% (vs. 18% Q1 2024). Adjusted EBITDA $2.3M vs. -$10.7M YoY.
- **Key Drivers**: Higher flower sales in Israel (+40% YoY), cost efficiencies, and regional mix shift. Operating expenses down $1M YoY due to lower marketing spend.
- **Cash Flow**: $838M cash on hand, $50M Q1 CapEx for GrowCo expansion. Expect elevated CapEx through H2 2025.

**【Q&A Key Takeaways】**
- **Supply Constraints**: Shortages reflect demand for high-quality products, not industry-wide issue. GrowCo expansion will resolve by H2 2025.
- **Gross Margin Outlook**: Blended Q4/Q1 margin (43-44%) is baseline. Long-term margin improvement expected with scale from GrowCo.
- **Israel Tariffs**: Vetoed by Finance Minister, but potential implementation risks. Cronos remains largest medical provider in Israel.


Cronos Group Inc. (CRON) Q1 2025 Earnings Call Transcript

- **Revenue Growth**: 35% YoY increase to $117.6 million, driven by Canada and Israel market dominance.
- **Profitability**: Adjusted gross margin nearly doubled to 26%, with $8.7 million OpEx savings.
- **Brand Leadership**: Spinach #1 in Canada, SOURZ gummies capture 23% market share, and PEACE NATURALS leads Israel with 24% flower share.
- **Financial Strength**: $859 million cash balance supports global expansion and R&D investments.
- **2025 Outlook**: Flat OpEx, expanded cultivation capacity, and strategic market entries poised for growth.

**【CEO Opening Remarks】**
- **Revenue Growth**: 35% year-over-year increase in 2024 net revenue to $117.6 million, driven by Canada and Israel markets.
- **Gross Margin Expansion**: Adjusted gross margin improved to 26% (from 14% in 2023), fueled by cost reductions and higher-margin flower sales.
- **Operational Efficiency**: $8.7 million reduction in operating expenses (18% decrease) through disciplined cost management.
- **Brand Leadership**: Spinach is #1 cannabis brand in Canada (6% flower market share), SOURZ gummies hold 23% market share, and Lord Jones is #3 in chocolate category.
- **International Expansion**: PEACE NATURALS leads Israel with 24% flower market share and growing presence in Germany and U.K.
- **Balance Sheet Strength**: $859 million in cash, enabling investments in GrowCo expansion and new market entries.

**【CFO Financial Commentary】**
- **Q4 2024 Results**: Consolidated net revenue $30.3 million (+27% YoY), adjusted EBITDA (-$7.2 million vs. -$14.8 million prior year), and positive operating cash flow of $18.8 million.
- **Gross Profit**: $10.8 million (36% margin), with $1.8 million adjustment for GrowCo inventory step-up.
- **CapEx**: $9.7 million in 2024 for GrowCo expansion and automation upgrades.
- **2025 Outlook**: Flat OpEx despite GrowCo integration, with focus on leveraging expanded cultivation capacity.

**【CEO Closing Remarks】**
- Emphasized Cronos' position as global cannabis leader with strong financial performance and innovation pipeline.
- Highlighted 2025 priorities: launching new products in international markets, optimizing supply chain with GrowCo expansion, and maintaining disciplined financial management.

Actual								0.2	-0.31	0.19	-0.31	-0.44	0.15	0.21	-0.36	-0.09	-0.05	-0.1	-0.21	-0.05	-0.01	0	-0.12	-0.01	-0.02	0.02	0.11	0.02	-0.1	0.07	0.02
Forecast								-0.0562	-0.0532	-0.0537	-0.07	-0.0888	-0.0767	-0.0801	-0.1057	-0.085	-0.056	-0.0561	-0.0525	-0.04	-0.03	-0.0175	-0.0433	-0.01	-0.0033	0.005	0	0.01	-0.1	0.07	0.02
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+455.87%	-482.71%	+453.82%	-342.86%	-395.50%	+295.57%	+362.17%	-240.59%	-5.88%	+10.71%	-78.25%	-300.00%	-25.00%	+66.67%	+100.00%	-177.14%	0.00%	-506.06%	+300.00%	0.00%	+100.00%	0.00%	0.00%	0.00%

CRON

CRON fundamentals

CRON Q4 2025 Earnings

Earnings Call

You can ask Aime

CRON

CRON fundamentals

CRON Q4 2025 Earnings

Earnings Call

CRON Earnings Call Summary for Q4/20258:30 AM on Feb 26, 2026

CRON Earnings Call Summary for Q3/20258:30 AM on Nov 6, 2025

CRON Earnings Call Summary for Q2/20258:30 AM on Aug 7, 2025

CRON Earnings Call Summary for Q1/20258:30 AM on May 8, 2025

CRON Earnings Call Summary for Q4/20248:30 AM on Feb 27, 2025

You can ask Aime